I  U  P  A  C

News & Notices

Organizations & People

Standing Committees







Links of Interest

Search the Site

Home Page


[Release, 17 Aug 2006]

Malcolm F.G. Stevens is Awarded
the First IUPAC-Richter Prize

The newly established IUPAC–Richter Prize in Medicinal Chemistry has been awarded in 2006 for the first time. The recipient is Professor Malcolm F.G. Stevens, Ph.D., D.Sc., OBE, of Nottingham University, U.K.

Dr. Stevens received this award in recognition of his leadership and contributions to the discovery of anticancer drugs. His work has resulted in the discovery of six novel small molecule agents that have progressed into clinical trials. Among them is Temozolomide (Temodal™), used to treat glioblastoma multiforme (a deadly brain cancer), which is licensed to the Schering-Plough Corporation and has been marketed worldwide since 1999. Another product, Phortress, is in early-stage clinical trial against breast tumors; other products from his current research, exploiting other mechanisms for anticancer agents, are also expected to enter development.

The IUPAC-Richter Prize -a plaque and a check for USD 10000- will be presented on 29 August 2006 at the XIXth International Symposium of Medicinal Chemistry in Istanbul, Turkey. The plaque is signed by Prof. Bryan Henry, president of IUPAC, and Erik Bogsch, chief executive officer of Gedeon Richter Limited.

Dr. Stevens studied pharmacy at the University of Nottingham, England, and obtained his Ph.D. in 1963, also at Nottingham. He was subsequently awarded a D.Sc. in 1979 for his published research on the novel synthesis of heterocyclic compounds. He pursued an academic career, spending 7 years as a lecturer in medicinal chemistry at Heriot-Watt University in Edinburgh, Scotland, and then as a reader (i.e., an associate professor) in medicinal chemistry at Aston University in Birmingham, England. He was appointed professor of experimental cancer chemotherapy at Aston in 1979, and starting in 1983, spent 6 years as head of the Department of Pharmaceutical Sciences. In 1992 he returned to Nottingham University as Cancer Research UK professor of experimental cancer chemotherapy and director of the Centre for Biomolecular Sciences, the position that he holds today. In addition, he is also chief scientific officer of Pharminox, a spin-off of Oxford University focused on the discovery and development of novel small molecule drugs for the treatment of cancer.

Dr. Stevens has received other forms of recognition from learned societies during his career: the UK Royal Society of Chemistry (RSC) Interdisciplinary Award (1991), the Royal Pharmaceutical Society of Great Britain Harrison Memorial Medal (1994), the RSC George and Christine Sosnovsky Award for chemical contributions to cancer research (2002), and the American Association for Cancer Research Bruce F. Cain Memorial Award (2003) for translational cancer research.

> Stevens' Homepage

> Back to IUPAC-Richter page


<prize announcement published in Chem. Int. Sep 2006 - see issue index>

Page last modified 21 September 2006.
Copyright ©1997-2006 International Union of Pure and Applied Chemistry.
Questions or comments about IUPAC, please contact, the Secretariat.
Questions regarding the website, please contact web manager.